Kevin Roggin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin Roggin has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Blase N. Polite
University of Chicago Medical Center, Chicago, IL
7 shared publications - Daniel V. T. Catenacci
University of Chicago, Chicago, IL
7 shared publications - Hedy Lee Kindler
University of Chicago Medicine, Chicago, IL
7 shared publications - Mitchell C. Posner
University of Chicago Comprehensive Cancer Center, Chicago, Illinois
7 shared publications - Douglas Kyle Hogarth
Department of Medicine, Section of Pulmonary & Critical Care, University of Chicago, Chicago, IL 60637, USA
6 shared publications - John Hart
Australian National University
6 shared publications
Latest Publications
- 26 September 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 17-23
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases
- 26 September 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 229, 17-23
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Supplementary Fig. 1: Mutation rate and ploidy for each individual patient's primary and metastatic sample (cohort 1);Supplementary Fig. 2: Validation of genomic heterogeneity within primary tumor and between primary tumor and lymph node (LN) metastases detected by next generation sequencing (NGS) with fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC);Supplementary Fig. 3: PANGEA: Platform clinical trial of molecularly driven therapies in patients with previously untreated GEA;Supplementary Fig. 4: Biomarker profiling of PANGEA where the biomarker profiling of the metastatic tumor did not lead to treatment reassignment relative to treatments assigned based upon the primary tumor
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Supplementary Fig. 1: Mutation rate and ploidy for each individual patient's primary and metastatic sample (cohort 1);Supplementary Fig. 2: Validation of genomic heterogeneity within primary tumor and between primary tumor and lymph node (LN) metastases detected by next generation sequencing (NGS) with fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC);Supplementary Fig. 3: PANGEA: Platform clinical trial of molecularly driven therapies in patients with previously untreated GEA;Supplementary Fig. 4: Biomarker profiling of PANGEA where the biomarker profiling of the metastatic tumor did not lead to treatment reassignment relative to treatments assigned based upon the primary tumor
- 28 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 3304-3305
ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms
- 28 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 3304-3305
ASO Visual Abstract: Extremity Soft Tissue Sarcoma—A Multi-institutional Validation of Prognostic Nomograms
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , S274
Role of Adjuvant Radiation Therapy for Retroperitoneal Sarcomas: An 8-Institution Study from the US Sarcoma Collaborative
- 1 October 2019
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 229 (4) , S274
Role of Adjuvant Radiation Therapy for Retroperitoneal Sarcomas: An 8-Institution Study from the US Sarcoma Collaborative